NCT03041181 - Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 27, 2017

Primary Completion Date

May 23, 2019

Study Completion Date

May 23, 2019

Conditions

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Adenocarcinoma of the LungLung CancerSquamous Cell Lung Cancer

Interventions

DRUG

Docetaxel

Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)

DRUG

Nivolumab

Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)

Trial Locations (9)

University of Virginia Health System, Charlottesville

St. Vincent Anderson Regional Hospital, Anderson

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

IU Health Central Indiana Cancer Center, Indianapolis

Community Regional Cancer Care, Indianapolis

Community Healthcare System, Munster

IU Health Ball Memorial Hospital Cancer Center, Muncie

HealthPartners Institute, Minneapolis

University of Texas Medical Branch at Galveston, Galveston